Why Did Novo Nordisk Seek an Injunction Against Lilly's GLP-1 Ads?

What Did Novo Nordisk File on 14 August 2026?

Novo Nordisk filed a motion for a preliminary injunction on Friday, 14 August 2026, in the US District Court for the District of New Jersey, asking a judge to immediately stop Eli Lilly from running its current obesity and diabetes drug advertising campaigns while the underlying lawsuit proceeds.[1] The court was scheduled to consider the motion three days later, on 17 August 2026.[1]

The motion is not a new lawsuit. It escalates the case Novo opened on 21 July 2026, when it sued Lilly alleging federal and state unfair-competition and false-advertising claims, including under the Lanham Act, over Lilly's direct-to-consumer marketing of Zepbound (tirzepatide) and Mounjaro against Novo's Wegovy and Ozempic (semaglutide).[2] Our original coverage of the July filing has the full background on that complaint.

Which Lilly Ads Does Novo Say Are Misleading?

Novo's filing centres on a specific television and social-media campaign that presents Zepbound and Wegovy in a direct side-by-side comparison, stating that patients on Lilly's drug lose 50 pounds on average, versus 33 pounds on the 2.4mg dose of Novo's Wegovy.[3] Novo argues the comparison is outdated: the FDA approved a higher, 7.2mg dose of Wegovy in March 2026, and Novo says omitting it creates a false impression of Zepbound's relative superiority using data that no longer reflects the highest dose patients can be prescribed.[4]

Novo's broader argument, as reported by Law360, is that consumers — unlike prescribing clinicians with access to full trial data — often form their understanding of a medicine's relative effectiveness primarily from advertising, which raises the stakes of an allegedly outdated comparison reaching a mass audience across TV and social platforms.[3]

What Has Eli Lilly Said in Response?

Lilly has denied wrongdoing and said it will defend the case vigorously. In a statement responding to the original complaint, the company said it stands "firmly behind our advertising," describing a robustly designed, well-conducted head-to-head clinical trial as "the gold standard for comparing medicines" and pointing to its own head-to-head trial data comparing Zepbound to Wegovy as the basis for its claims.[6] Lilly has separately said its messaging is "truthful," "transparent," and "grounded in the most direct scientific evidence available."[2]

As of publication, no ruling on the preliminary-injunction motion had been reported. Preliminary-injunction hearings typically address whether a plaintiff is likely to succeed on the underlying claim and whether it faces irreparable harm absent immediate relief; a hearing date is not the same as a decision, and the underlying Lanham Act case continues regardless of the motion's outcome.

How Does This Fit Into the Wider GLP-1 Advertising Fight?

The dispute sits inside a much larger commercial rivalry: Lilly's Mounjaro and Zepbound franchise took roughly 60.9% of the US obesity/diabetes market by revenue in Q2 2026 versus Novo's 38.8%, per Lilly's own earnings disclosures, which we covered in our Q2 2026 earnings report.[7] Advertising claims are one of the few levers either company can pull quickly in a market where new trial data arrives on a months-long cadence, which is part of why this dispute has moved from complaint to injunction motion in under a month.

It is also a separate track from the UK's own advertising-enforcement activity this year, including the MHRA's action against Tesco Pharmacy and the ASA's ruling against Bolt Pharmacy. Those cases concern UK pharmacies advertising prescription-only medicines to the public under the CAP Code; Novo v. Lilly is a US Lanham Act dispute between two manufacturers over comparative-claims advertising, litigated under different law in a different jurisdiction.

Does This Affect Retatrutide or UK Research-Reagent Supply?

No. This dispute concerns marketing claims for two already-licensed, FDA-approved drug franchises — Lilly's tirzepatide (Zepbound/Mounjaro) and Novo's semaglutide (Wegovy/Ozempic). It has no connection to retatrutide, Lilly's investigational triple-receptor peptide, which remains in its own separate TRIUMPH Phase 3 programme and unapproved by any regulator, or to any compound Velox Peptides supplies as a research reagent.[8] It also has no bearing on the Human Medicines Regulations 2012 or MHRA guidance governing lawful research-reagent supply in Great Britain and Northern Ireland.

Velox Peptides does not stock tirzepatide, semaglutide or any licensed medicine referenced here. This compound is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

What Happens Next?

We'll cover the ruling on Novo's injunction motion, and any material developments in the underlying case, as they're reported.

Frequently Asked Questions